Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
$733.04
$9.02(1.24%)
At close: 4:00 PM EST
$733.04
$9.02(1.24%)
Day’s Range― - ―
52-Week Range$476.49 - $821.11
Previous CloseN/A
Volume208.99K
Average Volume (3M)802.54K
Market Cap
$77.04B
Enterprise Value$58.46B
Total Cash (Recent Filing)$8.44B
Total Debt (Recent Filing)$2.71B
Price to Earnings (P/E)17.5
Beta0.75
Next Earnings
Jan 30, 2026EPS Estimate
10.52Next Dividend Ex-DateN/A
Dividend Yield0.45%
Share Statistics
EPS (TTM)11.83
Shares Outstanding103,282,320
10 Day Avg. Volume906,423
30 Day Avg. Volume802,539
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)2.62
Price to Sales (P/S)5.41
P/FCF Ratio20.97
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue4.10
Enterprise Value/Gross Profit4.81
Enterprise Value/Ebitda10.23
Forecast
1Y Price Target
$812.15Price Target Upside10.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)45.38
Revenue Forecast (FY)$15.38B
Bulls Say, Bears Say
Bulls Say
Dupixent Indication ExpansionDupixent's steady expansion into additional approved indications and its emergence as a core growth driver underpin raised sales expectations and have supported analyst upgrades and higher price targets.
Eylea High-dose Approval And UptakeCompleted resubmission and recent label enhancements for the high-dose Eylea formulation, together with strong uptake, could extend market share and remove a regulatory overhang that has weighed on the stock.
Sanofi Collaboration And Revenue MixGrowth in Sanofi collaboration revenue, including surpassing US Eylea revenue levels and plans to complete repayment of the development balance, could meaningfully boost profitability and free cash flow.
Bears Say
Biosimilar Competition And Loss Of ExclusivityBiosimilar entrants in the standard-dose Eylea market and eventual loss of exclusivity for Dupixent create pricing pressure and uncertainty for long-term franchise sales.
Standard-dose Eylea Sales SoftnessStandard-dose Eylea sales falling short of consensus signals softness in a key segment of the franchise and may limit near-term upside despite gains from the high-dose formulation.
Valuation And Pipeline Execution RiskThe stock trading in line with current valuation highlights that further upside depends on successful execution of diversification beyond core products, a material execution risk for investors.
Regeneron News
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $476.49 and its highest was $821.11 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $77.04B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Jan 30, 2026 which is in 11 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Oct 28, 2025. The company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.655 by $2.175.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 0.45%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 10.52.
How many shares outstanding does Regeneron have?
Regeneron has 103,282,320 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $11.83 in its last earnings report, beating expectations of $9.655. Following the earnings report the stock price went up 11.817%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$812.15 (10.79% Upside)
$812.15 (10.79% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 846.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.32%
12-Months-Change
Fundamentals
Return on Equity
15.19%
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
REGN Company Deck
REGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Regeneron demonstrated strong sales growth in key products like Dupixent and Libtayo, along with significant R&D pipeline progress. However, challenges such as affordability issues for EYLEA and FDA-related setbacks tempered some positive outcomes. Overall, the company shows a robust financial position and commitment to innovation, but faces operational hurdles that need addressing.View all REGN earnings summariesREGN Revenue Breakdown
53.72% Net product sales
42.65% Collaboration revenue
3.63% Other revenue
REGN Stock 12 Month Forecast
Average Price Target
$812.15
▲(10.79% Upside)
Technical Analysis
Ownership Overview
1.96% Insiders
24.41% Mutual Funds
0.51% Other Institutional Investors
45.45% Public Companies and Individual Investors